Unique ID issued by UMIN | UMIN000057691 |
---|---|
Receipt number | R000065887 |
Scientific Title | A Clinical trial on the Effects of test substance GL-2 on Posture and Fatigue : single blinded study |
Date of disclosure of the study information | 2025/04/23 |
Last modified on | 2025/04/21 16:57:00 |
A Clinical trial on the Effects of test substance GL-2 on Posture and Fatigue
A Clinical trial on the Effects of test substance GL-2 on Posture and Fatigue
A Clinical trial on the Effects of test substance GL-2 on Posture and Fatigue : single blinded study
A Clinical trial on the Effects of test substance GL-2 on Posture and Fatigue
Japan |
No
Adult |
Others
NO
To confirm the effect of test substance GL-2 on posture and fatigue
Efficacy
Quantification of standing posture after 2 weeks(image analysis)
Subjective evaluation after 2 weeks (fatigue)
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
No treatment
2
Treatment
Other |
2-week intervention of test substance GL-2
non-intervention(2-week)
20 | years-old | <= |
70 | years-old | > |
Male and Female
1.Healthy males and females aged 20 to 69 years-old.
2.Those who frequently feel foot fatigue or have flat feet
3.Subjects who stand or walk while wearing shoes for more than 5 hours per day, at least 5 days a week.
4.Subjects who walk more than 5,000 steps per day
5.Subjects who can make self-judgment and are voluntarily giving written informed consent.
Subjects (who)
1. are/might be pregnant or lactating during the current study periods.
2. spend less than 5 hours per day wearing shoes (Subjects who switch to sandals or other types of non-shoe footwear during the day).
3. do not experience fatigue in their legs in daily life.
4. are currently undergoing outpatient treatment for disorders of the foot or leg, or who have previously undergone foot surgery.
5. legs are affected by severe pain or disability.
6. are prohibited from engaging in physical activity by their physician.
7. have severe cardiac, respiratory, circulatory disorders, or other serious disease.
8. ability to exercise is restricted due to injuries or disabilities of the lower extremities.
9. are using specific medications that affect symptoms of the lower extremities.
10. have a smoking habit.
11. can't stop drinking from 2 days before each measurement.
12. have excessive alcohol intake more than 20 g/day of pure alcohol equivalent for more than 4 days a week.
13. are under treatment for or have a history of drug addiction and/or alcoholism.
14. have participated in other clinical studies within one month prior to obtaining informed consent, or plan to participate in other studies.
15. are judged as unsuitable for the current study by the investigator for other reasons.
30
1st name | Takeshi |
Middle name | |
Last name | Kaneko |
Japan Clinical Trial Association
N.A.
1600022
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
0364574666
info@yakujihou.org
1st name | Takeshi |
Middle name | |
Last name | Kaneko |
Japan Clinical Trial Association
N.A.
1600022
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
0364574666
info@yakujihou.org
Japan Clinical Trial Association
TOYO SHINYAKU Co., Ltd.
Profit organization
Institutional Review Board of Pharmaceutical Law Wisdoms
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
0364574911
master@yakujihou.net
NO
2025 | Year | 04 | Month | 23 | Day |
Unpublished
Preinitiation
2025 | Year | 03 | Month | 19 | Day |
2025 | Year | 04 | Month | 24 | Day |
2025 | Year | 05 | Month | 31 | Day |
2025 | Year | 04 | Month | 23 | Day |
2025 | Year | 04 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065887